And, it has been approved in September 2022 for the treatment of adult, previously treated, unresectable, locally advanced or metastatic FGFR2 fusions or rearrangements intrahepatic cholangiocarcinoma patients. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.